Proactive Investors - Run By Investors For Investors

Canntab Therapeutics shares nudge higher as latest quarterly results show surge in revenue

The company is developing advanced pharmaceutical grade formulations of cannabinoids
Canntab Therapeutics shares nudge higher as latest quarterly results show surge in revenue
The company is developing advanced pharmaceutical grade formulations of cannabinoids in pill form

Canntab Therapeutics Ltd (CSE:PILL) shares nudged higher in Toronto Friday as it posted its latest quarterly results, as revenue surged on the back of license fees other income.

Revenue from interest income and licence fees for the three months ended August 31 was $31,795 versus $682 in the same quarter a year ago.

The company ended the quarter with cash of $3.4 million, having invested $125,000 on equipment and intangible assets, as it continues in its development of cannabis pills.

READ: Canntab Therapeutics shares higher as pot pill firm enters Mexico market

In keeping for a company at this stage of early development, the quarterly loss was $446,856 versus a loss of $211,602 in the same quarter last year.

The company is developing advanced pharmaceutical grade formulations of cannabinoids and has developed technology to generate medical cannabis extract from selective strains in a variety of pharmaceutical dosages.

Last month it applied to become a licensed producer under Canada's medical purposes regulations.

It also revealed it was poised to enter the medicinal cannabis market in Mexico after signing a non-binding Letter of Intent (LOI) with Labsco Promedic SA de CV of Monterrey, Mexico over a joint venture for an initial period of five years.

Among the agreements, Labsco shall be responsible for funding and obtaining any regulatory, licencing or other such approvals for importing and distributing Canntab products in Mexico and will provide physical premises.

Canntab will license current patents and know-how, subject to completion of the deal.

Shares in Toronto added 2.29% to stand at $1.34.

Reporting by Giles Gwinnett

[email protected]

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full PILL profile View Profile

Canntab Therapeutics Ltd Timeline

Related Articles

The R&D programme is intended to address the increasing prevalence of obesity and diabetes using smart siRNA
October 31 2018
The health sciences company noted that the plan was formulated at a recently held two-day intensive workshop which together leading scientific teams from the QIMR Berghofer Medical Research Institute in Brisbane and Murdoch University in Perth
1542134062_Harvesting-hemp.jpg
November 14 2018
Ascent, viaThirty Eight Hemp Corp, will exploit the hemp market via its strategic relationship with AgTech Scientific
Cannabis leaf
November 19 2018
With the legalisation of recreational cannabis in Canada in October, and the US expected to follow suit, the company has its sights set on building up the very best in the industry

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use